ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2017

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.

Adrienne M Gilligan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.